Your browser doesn't support javascript.
Effectiveness of COVID-19 Convalescent Plasma (CCP) During the Pandemic Era: A Literature Review.
Kandula, Usha Rani; Tuji, Techane Sisay; Gudeta, Dinkinesh Begna; Bulbula, Kassech Leta; Mohammad, Anwar Abdulwahed; Wari, Ketema Diriba; Abbas, Ahmad.
  • Kandula UR; Department of Nursing, College of Health Sciences, Arsi University, Asella, Ethiopia.
  • Tuji TS; Department of Nursing, College of Health Sciences, Arsi University, Asella, Ethiopia.
  • Gudeta DB; Department of Nursing, College of Health Sciences, Arsi University, Asella, Ethiopia.
  • Bulbula KL; Department of Nursing, College of Health Sciences, Arsi University, Asella, Ethiopia.
  • Mohammad AA; Department of Nursing, College of Health Sciences, Arsi University, Asella, Ethiopia.
  • Wari KD; Department of Nursing, College of Health Sciences, Arsi University, Asella, Ethiopia.
  • Abbas A; Department of Nursing, College of Health Sciences, Arsi University, Asella, Ethiopia.
J Blood Med ; 14: 159-187, 2023.
Article in English | MEDLINE | ID: covidwho-2265393
ABSTRACT
Worldwide pandemic with coronavirus disease-2019 (COVID-19) was caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). As November 2, 2022, World Health Organization (WHO) received 628,035,553 reported incidents on COVID-19, with 6,572,800 mortalities and, with a total 12,850,970,971 vaccine doses have been delivered as of October 31, 2022. The infection can cause mild or self-limiting symptoms of pulmonary and severe infections or death may be caused by SARS-CoV-2 infection. Simultaneously, antivirals, corticosteroids, immunological treatments, antibiotics, and anticoagulants have been proposed as potential medicines to cure COVID-19 affected patients. Among these initial treatments, COVID-19 convalescent plasma (CCP), which was retrieved from COVID-19 recovered patients to be used as passive immune therapy, in which antibodies from cured patients were given to infected patients to prevent illness. Such treatment has yielded the best results in earlier with preventative or early stages of illness. Convalescent plasma (CP) is the first treatment available when infectious disease initially appears, although few randomized controlled trials (RCTs) were conducted to evaluate its effectiveness. The historical record suggests with potential benefit for other respiratory infections, as coronaviruses like Severe Acute Respiratory Syndrome-CoV-I (SARS-CoV-I) and Middle Eastern Respiratory Syndrome (MERS), though the analysis of such research is constrained by some non-randomized experiments (NREs). Rigorous studies on CP are made more demanding by the following with the immediacy of the epidemics, CP use may restrict the ability to utilize it for clinical testing, non-homogenous nature of product, highly decentralized manufacturing process; constraints with capacity to measure biologic function, ultimate availability of substitute therapies, as antivirals, purified immune globulins, or monoclonal antibodies. Though, it is still not clear how effectively CCP works among hospitalized COVID-19 patients. The current review tries to focus on its efficiency and usage in clinical scenarios and identifying existing benefits of implementation during pandemic or how it may assist with future pandemic preventions.
Keywords

Full text: Available Collection: International databases Database: MEDLINE Type of study: Experimental Studies / Prognostic study / Randomized controlled trials / Reviews Topics: Vaccines Language: English Journal: J Blood Med Year: 2023 Document Type: Article Affiliation country: JBM.S397722

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Type of study: Experimental Studies / Prognostic study / Randomized controlled trials / Reviews Topics: Vaccines Language: English Journal: J Blood Med Year: 2023 Document Type: Article Affiliation country: JBM.S397722